Spots Global Cancer Trial Database for ceralasertib
Every month we try and update this database with for ceralasertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | NCT03878095 | Malignant Solid... Refractory Chol... Refractory Mali... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | NCT04699838 | Extensive Stage... | Cisplatin Carboplatin Etoposide Durvalumab Ceralasertib | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer | NCT04564027 | Advanced Solid ... | Ceralasertib | 18 Years - 130 Years | AstraZeneca | |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | NCT04704661 | Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma... | Ceralasertib Trastuzumab Der... | 18 Years - | National Cancer Institute (NCI) | |
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | NCT04699838 | Extensive Stage... | Cisplatin Carboplatin Etoposide Durvalumab Ceralasertib | 18 Years - | Big Ten Cancer Research Consortium | |
| Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | NCT03878095 | Malignant Solid... Refractory Chol... Refractory Mali... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies | NCT05469919 | Advanced Solid ... | Ceralasertib | 18 Years - | AstraZeneca | |
| Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer | NCT03801369 | Anatomic Stage ... Metastatic Trip... | Biopsy Capivasertib Ceralasertib Durvalumab Olaparib Quality-of-Life... Selumetinib | 18 Years - | OHSU Knight Cancer Institute | |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC | NCT04550104 | Non Small Cell ... | Radiotherapy Olaparib Oral T... AZD1390 Ceralasertib AZD5305 Durvalumab | 18 Years - | University of Leeds | |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | NCT03682289 | Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast... | Ceralasertib Olaparib Durvalumab | 18 Years - | University of California, San Francisco | |
| Olaparib With Ceralasertib in Recurrent Osteosarcoma | NCT04417062 | Osteosarcoma Osteosarcoma Re... | Olaparib Ceralasertib | 12 Years - 40 Years | Dana-Farber Cancer Institute | |
| A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). | NCT03022409 | Head and Neck S... | Ceralasertib Olaparib | 18 Years - 130 Years | AstraZeneca | |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC | NCT04550104 | Non Small Cell ... | Radiotherapy Olaparib Oral T... AZD1390 Ceralasertib AZD5305 Durvalumab | 18 Years - | University of Leeds | |
| A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy | NCT05941897 | Advanced or Met... | Ceralasertib Durvalumab | 18 Years - | AstraZeneca | |
| A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy | NCT05450692 | Advanced or Met... | Ceralasertib Durvalumab Docetaxel | 18 Years - | AstraZeneca | |
| Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel | NCT05582538 | Triple Negative... | Ceralasertib Durvalumab Nab-paclitaxel | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel | NCT05582538 | Triple Negative... | Ceralasertib Durvalumab Nab-paclitaxel | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT03579316 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Adavosertib Olaparib Ceralasertib | 18 Years - | M.D. Anderson Cancer Center | |
| Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer | NCT03801369 | Anatomic Stage ... Metastatic Trip... | Biopsy Capivasertib Ceralasertib Durvalumab Olaparib Quality-of-Life... Selumetinib | 18 Years - | OHSU Knight Cancer Institute | |
| A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT03328273 | Chronic Lymphoc... | Ceralasertib Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC | NCT04550104 | Non Small Cell ... | Radiotherapy Olaparib Oral T... AZD1390 Ceralasertib AZD5305 Durvalumab | 18 Years - | University of Leeds | |
| Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT03579316 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Adavosertib Olaparib Ceralasertib | 18 Years - | M.D. Anderson Cancer Center | |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC | NCT04550104 | Non Small Cell ... | Radiotherapy Olaparib Oral T... AZD1390 Ceralasertib AZD5305 Durvalumab | 18 Years - | University of Leeds | |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | NCT03682289 | Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast... | Ceralasertib Olaparib Durvalumab | 18 Years - | University of California, San Francisco | |
| A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy | NCT05450692 | Advanced or Met... | Ceralasertib Durvalumab Docetaxel | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
